HC Wainwright restated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $14.00 target price on the stock.
PolyPid Stock Performance
Shares of NASDAQ PYPD opened at $3.75 on Thursday. The stock’s 50-day moving average is $3.82 and its 200 day moving average is $4.65. The stock has a market cap of $17.99 million, a price-to-earnings ratio of -0.30 and a beta of 1.31. PolyPid has a 1-year low of $2.95 and a 1-year high of $11.10. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.60.
Institutional Investors Weigh In On PolyPid
An institutional investor recently bought a new position in PolyPid stock. Rosalind Advisors Inc. purchased a new position in PolyPid Ltd. (NASDAQ:PYPD – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid comprises about 1.8% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 20th largest position. Rosalind Advisors Inc. owned approximately 8.67% of PolyPid at the end of the most recent reporting period. 26.47% of the stock is currently owned by institutional investors and hedge funds.
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Stories
- Five stocks we like better than PolyPid
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Top Stocks Investing in 5G Technology
- MarketBeat Week in Review – 8/12 – 8/16
- Business Services Stocks Investing
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.